If you have been reading about lipodystrophy and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
As a result of the party's shift, Labour Party leader Neil Kinnock made a public attack against the entryist group Militant at the 1985 Labour Party conference in Bournemouth. The Labour Party ruled that Militant was ineligible for affiliation with the Labour Party and the party gradually expelled Militant supporters. The Kinnock leadership had refused to support the 1984–1985 miner's strike over pit closures, a decision that the party's left-wing and the National Union of Mineworkers blamed for the strike's eventual defeat.
Hyperpigmentation, also known as dark spots, is the darkening of an area of skin or nails caused by increased melanin. Many topical treatments disrupt the synthesis of melanin by inhibiting the enzyme tyrosine hydroxylase.
=== Pharmacokinetics === The disposition of oveporexton is biexponential and it has an elimination half-life of 16 to 24 hours in humans. The FDA label gives a more specific mean terminal elimination half-life of 23.2 hours.
Sources: en.wikipedia.org
Until the 1960s, radioactivity was often handled naively and carelessly. From 1940 to 1945, the Berlin-based Auergesellschaft, founded by Carl Auer von Welsbach (1858-1929, Osram), produced a radioactive toothpaste called Doramad that contained thorium-X and was sold internationally. It was advertised with the statement, "Its radioactive radiation strengthens the defenses of the teeth and gums. The cells are charged with new life energy and the destructive effect of bacteria is inhibited. This gave the claim of radiant white teeth a double meaning. By 1930, there were also bath additives and eczema ointments under the brand name "Thorium-X". Radium was also added to toothpastes, such as Kolynos toothpaste. After World War I, radioactivity became a symbol of modern achievement and was considered "chic". Radioactive substances were added to mineral water, condoms, and cosmetic powders. Even chocolate laced with radium was sold. The toy manufacturer Märklin in the Swabian town of Göppingen tested the sale of an X-ray machine for children. At upper-class parties, people "photographed" each other's bones for fun. A system called Trycho (Ancient Greek: τριχο-, romanized: tricho-, lit. 'concerning the hair') for epilation (hair removal) of the face and body was franchised in the USA. As a result, thousands of women suffered skin burns, ulcers and tumors. It was not until the atomic bombings of Hiroshima and Nagasaki that the public became aware of the dangers of ionizing radiation and these products were banned.
==== Hydrogen ==== The isotopic reference frame of Standard Mean Ocean Water (SMOW) was established by Harmon Craig in 1961 by measuring δ2H and δ18O in samples of deep ocean water previously studied by Epstein & Mayeda (1953). Originally SMOW was a purely theoretical isotope ratio intended to represent the mean state of the deep ocean. In the initial work the isotopic ratios of deep ocean water were measured relative to NBS-1, a standard derived from the steam condensate of Potomac River water. Notably, this means SMOW was originally defined relative to NBS-1, and there was no physical SMOW solution. Following the advice of an IAEA advisory group meeting in 1966, Ray Weiss and Harmon Craig made an actual solution with the isotopic values of SMOW which they called Vienna Standard Mean Ocean Water (VSMOW). They also prepared a second hydrogen isotope reference material from firn collected at the Amundsen-Scott South Pole Station, initially called SNOW and later called Standard Light Antarctic Precipitation (SLAP). Both VSMOW and SLAP were distributed beginning in 1968. The isotopic characteristics of SLAP and NBS-1 were later evaluated by interlaboratory comparison through measurements against VSMOW (Gonfiantini, 1978). Subsequently, VSMOW and SLAP were used as the primary isotopic reference materials for the hydrogen isotope system for multiple decades. In 2006 the IAEA Isotope Hydrology Laboratory constructed new isotopic reference materials called VSMOW2 and SLAP2 with nearly identical δ2H and δ18O as VSMOW and SLAP.
=== South American think tanks === Research done by Enrique Mendizabal shows that South American think tanks play various roles depending on their origins, historical development and relations to other policy actors. In this study, Orazio Bellettini from Grupo FARO suggests that they:
Sources: en.wikipedia.org
=== 2025 parliamentary and regional elections === On 25 May 2025, Venezuela held elections for all 285 seats in the National Assembly, as well as most state governorships and regional legislatures. The ruling Great Patriotic Pole alliance led by the PSUV won nearly 83% of the vote for the Assembly and 23 of 24 state governorships, amid turnout of about 43% and a divided opposition in which some factions called for a boycott. Under the Constitution, deputies serve five-year terms, which implies that the following parliamentary election is due in 2030 unless early elections are called.
== Application == The application of APPI with LC/MS is commonly used for analysis of low polarity compounds such as petroleums, polyatomic hydrocarbons, pesticides, steroids, lipids, and drug metabolites lacking polar functional groups. Excellent review articles can be found in the References.
== Research == Moxidectin is being evaluated as a treatment for scabies. It is established in veterinary medicine to treat a range of parasites, including sarcoptic mange. Its advantage over ivermectin is its longer half-life in humans, thus the potential duration of action.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.